FinTrust Capital Advisors’s Genmab GMAB Stock Holding History

FinTrust Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.78K	Sell	196 -37	-16%	-$989	﹤0.01%	1099
2024 Q2	$5.86K	Buy	233 +37	+19%	+$1.05K	﹤0.01%	1006
2024 Q1	$5.86K	Buy	+196	New	+$5.76K	﹤0.01%	961
2023 Q4	–	Sell	-364	Closed	-$12.8K	–	1293
2023 Q3	$12.8K	Buy	+364	New	+$13.9K	﹤0.01%	742
2020 Q2	–	Sell	-165	Closed	-$3K	–	1095
2020 Q1	$3K	Hold	165	–	–	﹤0.01%	947
2019 Q4	$4K	Hold	165	–	–	﹤0.01%	889
2019 Q3	$3K	Buy	+165	New	+$3.25K	﹤0.01%	942

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FinTrust Capital Advisors's GMAB Position: Q3 2024 in Review

FinTrust Capital Advisors reduced its Genmab (GMAB) stake by 16% in Q3 2024, selling an estimated $989 and leaving 196 shares worth $4.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

FinTrust Capital Advisors first reported a position in GMAB in Q3 2019 and has held it in 7 quarters since. The position peaked at $12.8K in Q3 2023. 223 funds tracked by Wall St. Rank hold GMAB as of Q3 2024.

FinTrust Capital Advisors held 196 shares of Genmab worth $4.78K as of Q3 2024.
FinTrust Capital Advisors sold 37 Genmab shares in Q3 2024, an estimated $989.
Genmab made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1099 holding.
FinTrust Capital Advisors first reported a position in Genmab in Q3 2019 and has held it in 7 quarters since.
FinTrust Capital Advisors's Genmab position peaked at $12.8K in Q3 2023.
223 funds tracked by Wall St. Rank held Genmab as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.